umifenovir has been researched along with dabigatran in 1 studies
| Studies (umifenovir) | Trials (umifenovir) | Recent Studies (post-2010) (umifenovir) | Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) |
|---|---|---|---|---|---|
| 234 | 23 | 172 | 3,887 | 261 | 3,490 |
| Protein | Taxonomy | umifenovir (IC50) | dabigatran (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 4.7 | |
| Prothrombin | Homo sapiens (human) | 0.0046 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 8.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
1 other study(ies) available for umifenovir and dabigatran
| Article | Year |
|---|---|
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |